Trial record 15 of 161 for:    Encephalitis

A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Sanofi
ClinicalTrials.gov Identifier:
NCT00981175
First received: September 21, 2009
Last updated: July 11, 2012
Last verified: July 2012
  Purpose

The purpose of this study is to assess the safety, tolerability, immunogenicity, and duration of immunity of one or two doses of ChimeriVax™-JE vaccine separated by 5 or 6 months in adults.

Objectives:

Safety:

  • Obtain safety and tolerability data of a single, fixed dose of ChimeriVax™-JE compared with a placebo in adult volunteers (≥ 18 to <55 years) without prior Japanese encephalitis (JE) vaccination.

Immunogenicity:

  • Obtain data on the antibody response in adult volunteers following administration of ChimeriVax™-JE
  • Assess the durability of the immune response in adult volunteers over 60 months following one or two doses of ChimeriVax™-JE.

Condition Intervention Phase
Encephalitis
Japanese Encephalitis
Biological: Live attenuated Japanese encephalitis virus, then ChimeriVax diluent
Biological: ChimeriVax diluent, then Live attenuated Japanese encephalitis virus
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Randomised, Double-blind, Phase 2 Study of the Safety, Immunogenicity and Duration of Immunity of ChimeriVax™-JE, Live Attenuated Vaccine in Healthy Adults

Resource links provided by NLM:


Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Number of Participants With Seroconversion to Homologous ChimeriVax-JE Virus Strain After a Single Dose of Chimerivax™-JE and Placebo Dose [ Time Frame: Day 28 post-vaccination ] [ Designated as safety issue: No ]
    Assay by 50% Plaque Reduction Neutralization Test (PRNT50) Seroconversion: PRNT50 ≥ 10 and PRNT50 ≥ 20. Assessed in all participants who received ChimeriVax™-JE vaccine on Day 0 and Day 28.

  • Number of Participants Reporting Injection Site Treatment Emergent Adverse Events Post-Vaccination With ChimeriVax™-JE or Placebo at Day 0 and Day 28, and Following a Booster of ChimeriVax™-JE at Month 6 in a Subset of the Study Population. [ Time Frame: Days 0 to 28 post-vaccination ] [ Designated as safety issue: No ]
    Injection Site Treatment Emergent Adverse Events: Pain, Reaction Not Otherwise Specified (NOS), Erythema, Swelling, Bruising, Nodule, Pigmentation Changes, Pruritus were assessed in all participants for up to 28 days post-Vaccination.


Secondary Outcome Measures:
  • Number of Participants With Seroconversion to Homologous ChimeriVax™-JE Virus Strain After a Single Dose of Chimerivax™-JE and Placebo Followed by a Booster Vaccine Dose. [ Time Frame: Month 6 pre- and post-vaccination ] [ Designated as safety issue: No ]
    Assay by 50% Plaque Reduction Neutralization Test (PRNT50) Seroconversion: PRNT50 ≥ 10 and PRNT50 ≥ 20. Assessed in all participants who received ChimeriVax™-JE vaccine on Day 0 and Day 28 and pre- and post-Booster vaccination.

  • Number of Participants With Seroconversion to Homologous ChimeriVax™-JE Virus Strain After a Single Dose of Chimerivax™-JE and Placebo Followed or Not by a Booster Vaccine Dose at 6 Month. [ Time Frame: Month 12 post-vaccination ] [ Designated as safety issue: No ]
    Assay by 50% Plaque Reduction Neutralization Test (PRNT50) Seroconversion: PRNT50 ≥ 10 and PRNT50 ≥ 20. Assessed in all participants who received ChimeriVax™-JE vaccine on Day 0 and Day 28 and followed or not by a booster vaccine dose at 6 month.

  • Number of Participants With Seroconversion to Homologous ChimeriVax-JE Virus Strain After a Single Dose of Chimerivax™-JE and Placebo Followed or Not by a Booster Vaccine Dose at 6 Month. [ Time Frame: Month 24 post-vaccination ] [ Designated as safety issue: No ]
    Assay by 50% Plaque Reduction Neutralization Test (PRNT50) Seroconversion: PRNT50 ≥ 10 and PRNT50 ≥ 20. Assessed in all participants who received ChimeriVax™-JE vaccine on Day 0 and Day 28 and followed or not by a booster vaccine dose at month 24.

  • Number of Participants Reporting Treatment Emergent Adverse Events Recorded as Possibly, Probably, or Definitely Related to Study Treatment. [ Time Frame: Day 0 up to 28 post-vaccination ] [ Designated as safety issue: No ]
    Treatment emergent adverse events were assessed in all participants receiving ChimeriVax-JE Vaccine, Diluent (Placebo), or Booster Vaccination.


Enrollment: 202
Study Start Date: April 2003
Study Completion Date: February 2008
Primary Completion Date: June 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Study Group 1: ChimeriVax™-JE Vaccine first, then Placebo
Participants received ChimeriVax™-JE on Day 0 and ChimeriVax diluent on Day 28
Biological: Live attenuated Japanese encephalitis virus, then ChimeriVax diluent
ChimeriVax™-JE, 0.5 mL subcutaneous on Day 0; ChimeriVax diluent 0.5 mL subcutaneous on Day 28
Other Name: ChimeriVax™-JE
Experimental: Study Group 2: Placebo first, then ChimeriVax™-JE Vaccine
Participants received ChimeriVax diluent on Day 0 and ChimeriVax™-JE on Day 28.
Biological: ChimeriVax diluent, then Live attenuated Japanese encephalitis virus
ChimeriVax diluent, 0.5 mL subcutaneous on Day 0 and ChimeriVax™-JE, 0.5 mL subcutaneous on Day 28.
Other Name: ChimeriVax™-JE

Detailed Description:

Participants will receive ChimeriVax™-JE or diluent on Day 0 and diluent or ChimeriVax™-JE on Day 28. A subset of participants in each group will receive a booster dose of ChimeriVax™-JE at Month 6. Follow-up visits will occur at 12 and 24 months. Eligible participants will then enter the long-term immunogenicity follow-up period with visits at approximately 36, 48, and 60 months after Day 0. No safety data will be collected in the long-term immunogenicity follow-up period.

  Eligibility

Ages Eligible for Study:   18 Years to 54 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria :

At entry:

  • All aspects of the protocol explained and written informed consent obtained from the subject.
  • Aged ≥ 18 to < 55 years.
  • In good general health, without significant medical history, physical examination findings, or clinically significant abnormal laboratory results.
  • Subject must be available for the study duration, including all planned follow-up visits.
  • Has the subject agreed to take the following precautions to avoid insect bites for 7 days following vaccination: (a) wear long-sleeved shirts and trousers?; (b) apply N,N-Diethyl-meta-toluamide (DEET)-containing insect repellents?; (c) Sleep in screened enclosures?
  • For female subjects of childbearing potential: Negative serum pregnancy tests. An efficacious hormonal (i.e., oral, implantable or injectable) or barrier method of birth control must be used at least 1 month before Screening and Month 6 and at least 1 month after Day 28 and Month 6. These subjects will sign an agreement that birth control will be practised during the specified periods and will specify the method used. Female subjects unable to bear children must have this documented (e.g., tubal ligation or hysterectomy).

For long-term immunogenicity follow-up period:

  • Subject received an initial dose of ChimeriVax™-JE, has a baseline (Day 0) sample and at least one post-vaccination evaluable serological specimen for antibody analysis.
  • All aspects of the Long-term Immunogenicity Follow-up Period explained and updated written informed consent obtained from the subject.
  • In good general health, without significant medical history that may affect the efficacy endpoints or the ability to take blood samples.

Exclusion Criteria :

  • A history of vaccination to Japanese encephalitis (JE). Previous vaccination will be determined by history (interview of subject) and/or by reviewing the subject's vaccination card or other official documentation (either a history of or documentation of vaccination fulfils the criterion for exclusion).
  • Known or suspected immunodeficiency (e.g., human immunodeficiency virus [HIV] infection, primary immunodeficiency disorder, leukemia, lymphoma), use of immunosuppressive or antineoplastic drugs (corticosteroids > 10 mg prednisone, or equivalent, for more than 14 days in the last three months).
  • Clinically significant abnormalities on laboratory assessment.
  • Serious adverse reactions characterised by urticaria or angioedema to a prior vaccine.
  • Transfusion of blood or treatment with any blood product, including intramuscular or intravenous serum globulin within six months of the Screening Visit or up to Day 56.
  • Administration of another vaccine within 30 days preceding the screening visit or up to Day 56 (these subjects will be rescheduled for vaccination at a later date).
  • Physical examination indicating any clinically significant medical condition.
  • Body temperature >38.1°C (100.6°F) or acute illness within 3 days prior to inoculation (subject may be rescheduled).
  • Intention to travel out of the area prior to the study visit on Day 56.
  • Seropositive to hepatitis C virus (HCV) or HIV or positive for hepatitis B (HBV) (antigen).
  • Lactation or intended pregnancy in female subjects.
  • Excessive alcohol consumption, drug abuse, significant psychiatric illness.
  • A known or suspected physiological or structural condition that compromises the integrity of the blood-brain barrier (e.g., significant hypertensive cerebrovascular disease, trauma, ischemia, infection, inflammation of the brain).

For long-term immunogenicity follow-up period:

  • History of Yellow Fever or out of study JE vaccination or known flavivirus infection since receiving ChimeriVax™-JE vaccination on Day 0 or Day 28 (during double-blind treatment period of the study). Yellow Fever/JE vaccination or flavivirus infection will be determined by history (interview of subject) and/or by reviewing the subject's medical records. Please note subjects who were flavivirus positive at Day 0 will be allowed to enrol on the study.
  • Participation in another JE clinical study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00981175

Locations
Australia, Queensland
Enoggera, Queensland, Australia, 4051
Sponsors and Collaborators
Sanofi
Investigators
Study Director: Medical Director Sanofi Pasteur Inc.
  More Information

Additional Information:
Publications:
Responsible Party: Sanofi
ClinicalTrials.gov Identifier: NCT00981175     History of Changes
Other Study ID Numbers: H-040-005
Study First Received: September 21, 2009
Results First Received: April 5, 2011
Last Updated: July 11, 2012
Health Authority: Australia: National Health and Medical Research Council
United States: Food and Drug Administration

Keywords provided by Sanofi:
Japanese Encephalitis
Japanese Encephalitis Vaccines
Adult

Additional relevant MeSH terms:
Encephalitis
Encephalitis, Japanese
Encephalitis, Arbovirus
Encephalitis, Viral
Central Nervous System Viral Diseases
Virus Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Central Nervous System Infections
Arbovirus Infections
RNA Virus Infections
Flavivirus Infections
Flaviviridae Infections

ClinicalTrials.gov processed this record on August 18, 2014